Oct. 22.-24. 2022
T020 (136) Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
T021 (124) Radiation-Free Therapy as the INitial treatment of Good-prognosis early non-bulky Hodgkin lymphoma, defined by a low Metabolic Tumor Volume and a negative PET-2 - RAFTING Trial.
T022 (63) Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
P023 (104) PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma
P024 (142) Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
P025 (150) RADAR: An international phase III, PET response-adapted, randomised trial in progress, comparing ABVD±ISRT with brentuximab vedotin+AVD±ISRT in patients with previously untreated limited-stage classical Hodgkin lymphoma.
T064 (169) Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors
T065 (58) Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway
T066 (182) Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.
P067 (133) A pilot of lung cancer screening for survivors of Hodgkin lymphoma
P068 (157) A Retrospective Analysis of Fertility in Female Patients with Advanced Stages of Hodgkin Lymphoma Treated with BEACOPP Escalated Chemotherapy (25 Year Experience of a Single Centre)
P069 (95) Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients
P070 (81) Design of the INSIGHT study, evaluation of long-term follow-up care for lymphoma survivors in the Netherlands: does survivorship care at the BETER clinics reduce morbidity and mortality from late effects of lymphoma treatment and associated costs?
P071 (100) First results of cardiovascular screening in a survivorship care program for Hodgkin lymphoma survivors in the Netherlands
P072 (130) Impact of Ageing on the Survivorship Experiences of Patients with Hodgkin Lymphoma
P073 (107) Increased risk of colorectal cancer following treatment for Hodgkin lymphoma
P074 (72) Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients – A Nationwide Danish Cohort Study
P075 (160) My Hodgkin, My Health: Feasibility of a mobile application to collect long term follow up data about Hodgkin patients.
P076 (98) Pneumococcal infection in splenectomised Hodgkin lymphoma patients: Do they pose a problem today and what is the best long-term strategy?
P077 (108) Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
P078 (106) Predicting the Health-Related Quality of Life of Hodgkin Lymphoma Survivors: Identification of Risk Factors
P079 (109) PROCTCAE as a patient-reported outcome measurement (PROM) questionaire in patients with Hodgkin Lymphoma captures different adverse events profile than those reported by physicians
P080 (64) The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment
P081 (118) Treatment-related circulatory diseases and mortality in Hodgkin lymphoma patients using multi-state modelling and relative survival
T082 (147) AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.
T083 (127) The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma
T084 (71) Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry
T057 (59) Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume
P061 (174) Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
P059 (129) Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
P060 (167) Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
P062 (166) The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
P063 (189) Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial
T058 (179) Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment
T001 (134) FDG-PET and serum TARC levels after one cycle of BV-AVD in advanced stage Hodgkin lymphoma patients: results from the very early PET-response adapted EORTC-COBRA trial
T002 (193) Treatment related morbidity in patients with classical Hodgkin Lymphoma: results of the ongoing, randomized phase III HD21 Trial by The German Hodgkin Study Group
P003 (92) A retrospective study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered in the lymphoma clinic at Tata Memorial Centre.
P004 (80) Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
P005 (66) Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.
P006 (135) Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
P007 (178) Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
P008 (57) Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
P009 (99) Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
P010 (121) Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
P011 (188) IPS-7 or IPS-3 to identify very-high risk patients in advanced Classical Hodgkin ́s Lymphoma: Which score to choose
P012 (131) Nodular Lymphocyte-predominant Hodgkin Lymphoma a rare disease with good prognosis: a retrospective multicenter experience
P013 (103) Outcomes of first-line treatment (FL) of classical Hodgkin lymphoma (cHL) in Argentina: a real life multicenter retrospective study
P014 (186) Prognostic significance of nutritional indexes (CONUT and PNI) in classical Hodgkin lymphoma patients
P015 (94) Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity
P016 (152) Reduced steroid exposure is safe and does not reduce disease control among Hodgkin Lymphoma patients treated with escalated BEACOPP (eBEACOPP)
P017 (187) The role of baseline bulk and dissemination measures as predictors of progression in advanced Hodgkin lymphoma.
P018 (70) Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry
P019 (177) Unfavorable prognostic value of the predominance of THRLBCL-like histopathological growth patterns in nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
T026 (132) Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
T027 (115) High serum levels of Thymus and Activation Related Chemokine (TARC) precede Hodgkin lymphoma diagnosis by several years
T028 (159) Single-cell RNA sequencing reveals the interplay between circulating CD4 T cells, B cells and cancer-associated monocytes in classic Hodgkin lymphoma treated with PD-1 blockade
P029 (191) Are Reed-Sternberg cells stuck in mitosis by short nucleoplasmic bridges as a consequence of centromeric instability?
P030 (172) Baseline IgM amount can identify patients with adverse outcome despite a PET-2 adapted treatment in classical Hodgkin Lymphoma: results from a real-life single-center study i
P031 (101) CD4+ T cells in close proximity to Hodgkin-Reed Sternberg cells are antigen experienced, polyclonal and display an exhausted phenotype
P032 (139) Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
P033 (155) Clinical significance of the severity of THRLBCL-like areas in nodular lymphocyte predominant Hodgkin lymphoma
P034 (82) Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
P035 (93) CRISPR/Cas9-mediated knockout reveals an important role of CD30 in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma
P036 (125) Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma
P037 (137) High breadth whole exome sequencing of circulating tumor DNA identifies novel recurrent genetic alterations in Hodgkin lymphoma
P038 (117) HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
P039 (102) HLA expression status and prognostic impact of B-cell content in patients with early-stage unfavorable Hodgkin lymphoma
P040 (173) LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells
P041 (74) Low percentage of T lymphocytes in Hodgkin's Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
P042 (185) Metabolic regulation of adaptive response to arginine deprivation in Hodgkin Lymphoma
P043 (110) Molecular pathogenesis of Hodgkin lymphoma
P044 (161) PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
P045 (79) Plasma proteome profiling of cardiotoxicity in patients with Hodgkin lymphoma
P046 (138) Preclinical evaluation of novel repurposed drug combinations in Hodgkin lymphoma
P047 (164) Predictive role of the Hodgkin lymphoma-associated cytokines: a prospective study of the Czech Hodgkin Study Group
P048 (112) Predictors of risk of relapse in classic Hodgkin lymphoma by flow cytometry
P049 (114) Reduced features of T-cell activation before and during anti-PD-1 treatment in classical Hodgkin lymphoma
P050 (168) Reed-Sternberg cells accelerate glycolytic and mitochondrial metabolism of tumor microenvironment cells
P051 (146) Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
P052 (78) Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
P053 (158) The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
P054 (86) The Kinase CK2 is deregulated and targetable in classical Hodgkin Lymphoma
P055 (111) Validation of the tumor cell-specific rearranged IgG-encoding circulating cell-free DNA for the treatment response monitoring in patients with classic Hodgkin lymphoma
P056 (156) Variants of the transcription factor ONECUT2 regulate gene expression in Hodgkin Lymphoma cells
P115 (77) Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma
T098 (163) Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
T099 (149) High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
T100 (181) Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
P101 (165) Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin's lymphoma.
P102 (91) Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
P103 (190) Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
P104 (122) Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
P105 (145) Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
P106 (140) Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience